Arterial thrombosis frequently leads to death or disability from stroke, peripheral arterial
disease, or myocardial infarction (MI). Treating the underlying causes of these diseases is …

Dual antiplatelet therapy with aspirin, a platelet cyclooxygenase-1 inhibitor and P2Y12
receptor blockers, remains the major drug strategy to prevent ischemic event occurrence in …

Pharmacological management of thrombotic complications is strongly influenced by
antiplatelet treatment strategies. Recent clinical trials have clearly indicated that current …

In spite of treatment with the current standard of care antiplatelet regimens including dual
antiplatelet therapy, recurrence rates of ischemic events remain elevated for high-risk …

Compounds which inhibit the coagulation cascade and antagonize platelet function are
fundamental to the successful treatment of acute coronary syndromes. In a high proportion of …

This review describes the current status of antiplatelet therapy in prevention of
cardiovascular events of an atherothrombotic nature. The efficacy of aspirin clearly …

Oral antiplatelet therapies for secondary prevention of ischemic recurrences in patients with
atherosclerotic disease manifestations include aspirin and P2Y12 receptor antagonists …

Antiplatelet therapy has been successful in reducing mortality and morbidity in acute
myocardial infarction. Recent advances in understanding the molecular basis of the role of …

Platelets are now regarded as playing a dominant role in cardiovascular medicine since our
recent understanding of acute coronary syndrome as an atherothrombotic process. This …

The clinical pharmacology of antiplatelet drugs has been reviewed previously by the
European Society of Cardiology (ESC) Task force and by the 8th American College of Chest …